Cristina Gasparetto, MD, Duke University Medical Center

Articles by Cristina Gasparetto, MD, Duke University Medical Center

Teclistamab in RRMM: Patient Selection and Combining Therapies

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke University Medical Center,Rafael Fonseca, MD,Omar Nadeem, MD

July 28th 2022

Shifting toward the practical use of bispecific antibody teclistamab in RRMM, experts consider appropriate patient selection and investigational combination strategies.

BCMA-Targeting Bispecifics in RRMM: MajesTEC-1 Trial and Real-World Data for Teclistamab

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke University Medical Center,Rafael Fonseca, MD,Omar Nadeem, MD

July 28th 2022

Focusing on relapsed/refractory MM, expert panelists review data from MajesTEC-1 and consider how bispecific antibodies are impacting the treatment paradigm.

RRMM: Treatment Options in Early Relapse and in Triple-Class Refractory MM

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke University Medical Center,Rafael Fonseca, MD,Omar Nadeem, MD

July 21st 2022

Ajai Chari, MD provides an overview of treatment options in patients with multiple myeloma at first relapse and those with triple-refractory disease

Selecting Optimal Therapy in Transplant-Ineligible NDMM and Key Takeaways

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke University Medical Center,Rafael Fonseca, MD,Omar Nadeem, MD

July 21st 2022

Expert hematologist-oncologists home in on clinical trial data to consider which regimens are most appropriate for patients with transplant-ineligible NDMM.

Dr. Gasparetto on Managing Keratopathy Associated With Belantamab Mafodotin in Myeloma

ByCristina Gasparetto, MD, Duke University Medical Center

December 15th 2021

Cristina Gasparetto, MD, discusses how to manage keratopathy associated with treatment with belantamab mafodotin-blmf in patients with multiple myeloma.

Latest Updated Articles

RRMM: Treatment Options in Early Relapse and in Triple-Class Refractory MM
July 21st 2022
BCMA-Targeting Bispecifics in RRMM: MajesTEC-1 Trial and Real-World Data for Teclistamab
July 28th 2022
Selecting Optimal Therapy in Transplant-Ineligible NDMM and Key Takeaways
July 21st 2022
Teclistamab in RRMM: Patient Selection and Combining Therapies
July 28th 2022

Cristina Gasparetto, MD, Duke University Medical Center

Articles by Cristina Gasparetto, MD, Duke University Medical Center

Teclistamab in RRMM: Patient Selection and Combining Therapies

BCMA-Targeting Bispecifics in RRMM: MajesTEC-1 Trial and Real-World Data for Teclistamab

RRMM: Treatment Options in Early Relapse and in Triple-Class Refractory MM

Selecting Optimal Therapy in Transplant-Ineligible NDMM and Key Takeaways

Dr. Gasparetto on Managing Keratopathy Associated With Belantamab Mafodotin in Myeloma

Latest Updated Articles

Trending on OncLive

HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA

Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg

Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis

Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL

ESAONA Data Support Asandeutertinib as a Frontline Option in EGFR+ NSCLC With Brain Metastases